[Toxicity and antitumoral activity of two new complex compounds of rhenium].
Toxicity and antitumor action of two new complex compounds of rhenium (K2 [ReCl6] and [ReCl(4).2C6H4N2]) were investigated. LD50 of K2 [ReCl6], i.v., was 136 +/- 37 mg/kg; i.p.,--272 +/- 74 mg/kg. LD50 of [ReCl(4).2C6H4N2], i.v., was 543 +/- 148 mg/kg; i.p., 600 mg/kg was tolerable. Single maximum tolerable dose of 200 mg/kg K2 [ReCl6], i.p., did not influence the growth of ascitic tumor of Ehrlich, nor did daily intravenous dose of 50 mg/kg inhibit solid tumor of Ehrlich. No inhibition by [ReCl(4).2C6H4N2] was registered when 25 or 50 mg/kg were administered.
Natorkhin
M I
MI
N.N. Petrov Research Institute of Oncology, Ministry of Health of the RF, St. Petersburg.
Stukov
A N
AN
Filov
V A
VA
D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology* / Q000633:toxicity; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000633:toxicity; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy* / Q000517:prevention & control*; D004354:Drug Screening Assays, Antitumor; D009942:Organometallic Compounds / Q000494:pharmacology* / Q000633:toxicity; D017680:Potassium Compounds / Q000494:pharmacology* / Q000633:toxicity; D012211:Rhenium
D016588:Anticarcinogenic Agents; D000970:Antineoplastic Agents; D009942:Organometallic Compounds; D017680:Potassium Compounds; D012211:Rhenium